RxDoctor Payments Data

Norma Christian

Adult Health · Bronx, NYNPI 1326235888

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 55 payments — averaging $35.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$659
  • Abbott$614
  • Actelion Pharmaceuticals US, Inc.$347
  • United Therapeutics Corporation$212
  • Novartis$40
  • Pfizer$22
  • plus $66 from 4 others

What the payments were for

  • Consulting fees$60031%
  • Food & beverage$1,14759%
  • Education$21311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,959 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$4,963
Medicare patients
26
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan96$1,196,513
VyndamaxTafamidis28$763,556
UptraviSelexipag26$509,864
AdempasRiociguat33$501,290
EntrestoSacubitril/Valsartan217$248,669
Ambrisentan58$222,337
Orenitram ErTreprostinil Diolamine26$198,413
EliquisApixaban98$103,108
Tadalafil67$96,895
FarxigaDapagliflozin Propanediol68$88,191
AdcircaTadalafil17$69,002
JardianceEmpagliflozin55$56,765
VeltassaPatiromer Calcium Sorbitex15$35,783
Sildenafil Citrate15$7,714
Metoprolol Succinate167$3,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$347$1,706,377122 claims
PfizerVyndamax, Eliquis$22$866,664126 claims
BayerAdempas$659$501,29033 claims
NovartisEntresto$40$248,669217 claims
AstraZenecaFarxiga$18$88,19168 claims
United Therapeutics CorporationAdcirca$212$69,00217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.

Other adult health in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →